Aprameya Engineering Ltd
Incorporated in September 2003, Aprameya Engineering Limited specializes in installing and maintaining Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatres, and prefabricated structure wards in hospitals and medical care centers.[1]
- Market Cap ₹ 529 Cr.
- Current Price ₹ 278
- High / Low ₹ 308 / 61.2
- Stock P/E 21.5
- Book Value ₹ 37.3
- Dividend Yield 0.00 %
- ROCE 31.1 %
- ROE 36.8 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 90.1% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.2%
Cons
- Stock is trading at 7.36 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 320 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 12 | 26 | 35 | 78 | 65 | 136 | 169 | |
| 11 | 24 | 25 | 69 | 59 | 111 | 132 | |
| Operating Profit | 2 | 2 | 10 | 9 | 6 | 24 | 37 |
| OPM % | 13% | 9% | 29% | 12% | 10% | 18% | 22% |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | |
| Interest | 1 | 1 | 0 | 2 | 2 | 3 | 4 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 2 | 10 | 7 | 5 | 22 | 33 |
| Tax % | 8% | 44% | 25% | 28% | 24% | 26% | |
| 1 | 1 | 7 | 5 | 3 | 16 | 25 | |
| EPS in Rs | 10.66 | 3.84 | 2.49 | 8.47 | 12.92 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 62% |
| 3 Years: | 57% |
| TTM: | 108% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 90% |
| 3 Years: | 29% |
| TTM: | 362% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 323% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 30% |
| Last Year: | 37% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 7 | 14 | 14 | 19 | 19 |
| Reserves | 0 | 0 | 7 | 6 | 9 | 45 | 52 |
| 4 | 1 | 14 | 29 | 42 | 30 | 37 | |
| 6 | 5 | 20 | 13 | 10 | 49 | 26 | |
| Total Liabilities | 14 | 11 | 49 | 62 | 76 | 144 | 135 |
| 1 | 1 | 2 | 1 | 1 | 1 | 1 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 13 | 10 | 47 | 60 | 74 | 143 | 133 | |
| Total Assets | 14 | 11 | 49 | 62 | 76 | 144 | 135 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 0 | 4 | 10 | -13 | -10 | -11 | |
| -1 | 0 | -0 | -2 | -1 | -0 | |
| 1 | -4 | -8 | 13 | 11 | 11 | |
| Net Cash Flow | 0 | -0 | 2 | -2 | 0 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 182 | 58 | 278 | 195 | 325 | 320 |
| Inventory Days | 245 | 122 | 455 | 376 | 74 | |
| Days Payable | 269 | 147 | 1,100 | 415 | 146 | |
| Cash Conversion Cycle | 159 | 33 | -367 | 157 | 253 | 320 |
| Working Capital Days | 40 | 36 | 200 | 116 | 153 | 166 |
| ROCE % | 35% | 59% | 25% | 12% | 31% |
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
11 November 2025 - H1FY26 earnings/analyst call on Nov 14, 2025 at 3:30 PM IST discussing unaudited H1 results.
-
Outcome of Board Meeting
10 November 2025 - Unaudited H1 (30 Sep 2025): revenue Rs4,213.98 lakh; PAT Rs676.08 lakh; limited review 10 Nov 2025.
-
Outcome of Board Meeting
10 November 2025 - Board approved H1 results for 30 Sep 2025: Revenue Rs 4,213.98L, PAT Rs 676.08L.
-
Disclosure of material issue
5 October 2025 - Aprameya incorporated Aprameya Medtech Pvt Ltd on Oct 4, 2025; paid-up ₹50,00,000; Aprameya holds 70%.
-
Trading Window
22 September 2025 - Trading window closed from 1 Oct 2025 until 48 hours after results for quarter ended 30 Sep 2025.
Annual reports
Concalls
-
May 2025Transcript PPT REC
Business Segments
A) Healthcare Infrastructure Projects[1][2]
The company offers turnkey solutions for developing healthcare facilities, covering everything from design to execution of ICUs, NICUs, PICUs, Modular Operation Theatres (MOTs), Dialysis Centers, and Prefabricated Wards. The scope also includes integration of MEP systems, fire safety, structural design, and hospital interiors. These projects are tailored for public healthcare institutions, focused on customized infrastructure delivery.